🇺🇸 FDA
Patent

US 9320793

Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 9320793 (Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42) held by Acumen Pharmaceuticals, Inc. expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Acumen Pharmaceuticals, Inc.
Grant date
Tue Apr 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P